Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Three dates available!
Wednesday, September 4, 2019, 11:00 AM - 12:00 PM CT - Register to attend September 4
Thursday, September 19, 2019, 11:00 AM - 12:00 PM CT - Register to attend September 19
Wednesday, October 30, 2019, 10:30 AM - 11:30 AM CT - Register to attend October 30
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Infectious diseases practice is undergoing significant change in the management of nosocomial bacterial pneumonia. Categorized as HABP (hospital-acquired bacterial pneumonia) or VABP (ventilator-associated bacterial pneumonia), rapidly evolving drug resistance has had profound implications on disease progression and mortality. Rising threats from multi-drug resistant organisms, such as Pseudomonas aeruginosa, has created a need for thoughtful stewardship and use of combination antibiotics most likely to provoke a meaningful response. This activity will discuss the prevention and treatment of HABP/VABP for clinical and infectious diseases pharmacists. Special attention will be given to available and emerging treatment options, along with pertinent patient considerations and monitoring strategies.
The target audience for this activity includes pharmacists, nurses and physicians. At the completion of this activity, the participant will be able to:
Rachel Bystritsky, MD
Assistant Professor, Medicine
University of California, School of Medicine
San Francisco, CA
Katherine Gruenberg, PharmD, BCPS
Assistant Professor of Clinical Pharmacy
University of California, San Francisco School of Pharmacy
San Francisco, CA
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-435-L01-P has been assigned to this live knowledge-based activity (initial release date 9-4-2019). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical
Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CME credit provided by AKH Inc., Advancing Knowledge in Healthcare. This activity
is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and ProCE, Inc.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and ProCE, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of ProCE, Inc. and AKH Inc. to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of its continuing education activities. Faculty
must disclose to the participants any significant relationships with commercial interests
whose products or devices may be mentioned in the activity or with the commercial
supporter of this continuing education activity. Identified conflicts of interest
are resolved by AKH prior to accreditation of the activity and may include any of
or combination of the following: attestation to non-commercial content; notification
of independent and certified CME/CE expectations; referral to National Author Initiative
training; restriction of topic area or content; restriction to discussion of science
only; amendment of content to eliminate discussion of device or technique; use of
other author for discussion of recommendations; independent review against criteria
ensuring evidence support recommendation; moderator review; and peer review.
Dorothy Caputo, MA, BSN, RN - AKH Director of Accreditations and AKH planners and reviewers have no financial relationships to disclose.
Dr. Katherine Gruenberg has no relevant commercial or financial relationships to disclose.
Dr. Rachel Bystritsky has no relevant commercial or financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information
to assist in his/her practice and professional development and is not to be considered
a diagnostic tool to replace professional advice or treatment. The course serves as
a general guide to the healthcare professional, and therefore, cannot be considered
as giving legal, nursing, medical, or other professional advice in specific cases.
AKH Inc. specifically disclaim responsibility for any adverse consequences resulting
directly or indirectly from information in the course, for undetected error, or through
participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity is supported by an educational grant from Merck.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
Instructions for Participation and Credit:
For information on applicability and acceptance of continuing education credit for this activity please consult your professional licensing board.
This activity was designed to be completed within the time designated; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online. To receive AMA PRA Category 1 Credit(s)™, you must complete an online post-test and evaluation.
Follow these steps to earn CME credit:
1. Read the target audience, learning objectives and faculty disclosures.
2. Study the educational content online
3. Online, choose the best answer to each posttest question. Complete the evaluation.
4. Print your certificate online
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.